Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › Novo Nordisk’s stock slumps after failed trial — adding...
Business & Finance

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
MarketWatch Friday 31 July 2026, 13:54 UTC By Nora Redmond 1 min read
Key Points

The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.

The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure. [Image text:] O R novo nordisk
Novo Nordisk’s (ORG) Danish (ORG)
Originally published by MarketWatch Read original →

Related Stories

A spot is opening up in the S&P 500, and these stocks are top candidates to fill the void

Videogame publisher EA is set to be taken private, opening the door for a new company to join the benchmark index.

MarketWatch 10m ago

U.S. lawmakers request information from DoorDash on use of Chinese AI models

U.S. lawmakers have requested information from food delivery company DoorDash on its use of Chinese artificial intelligence models, CNBC has learned, as scrutiny around American businesses' use of systems developed by China ramps up. In a letter obtained by CNBC, the chairmen of two House Select Committees conducting a joint investigation into security implications of U.S. companies using Chinese AI models asked DoorDash to share "information and documents" relating to its evaluation and...

CNBC 21m ago

Healey announces his first Budget will be on 28 October

The new chancellor pledged to move money and power out of Westminster, and into every postcode around Britain.

BBC Business 28m ago

Healey announces his first Budget will be on 28 October

The new chancellor pledged to move money and power out of Westminster, and into every postcode around Britain.

BBC News 28m ago